CN112608865A - 一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 - Google Patents
一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 Download PDFInfo
- Publication number
- CN112608865A CN112608865A CN202011525162.9A CN202011525162A CN112608865A CN 112608865 A CN112608865 A CN 112608865A CN 202011525162 A CN202011525162 A CN 202011525162A CN 112608865 A CN112608865 A CN 112608865A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- function
- strain
- triglyceride
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 80
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 235000021107 fermented food Nutrition 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 239000002068 microbial inoculum Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 23
- 230000015556 catabolic process Effects 0.000 abstract description 11
- 238000006731 degradation reaction Methods 0.000 abstract description 11
- 244000005700 microbiome Species 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 33
- 239000001963 growth medium Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 238000000855 fermentation Methods 0.000 description 20
- 230000004151 fermentation Effects 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000003833 bile salt Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000010802 sludge Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N L-glucitol Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 235000015193 tomato juice Nutrition 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于微生物技术领域,特别涉及一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用。所述菌株命名为鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01‑013,该菌株已于2020年03月25日保藏在“中国微生物菌种保藏管理委员会普通微生物中心”,保藏号为CGMCC No.19510。所述的鼠李糖乳杆菌具有降甘油三酯功能,降解率达44.3%。将鼠李糖乳杆菌制成冻干粉后稳定性较强,所述的鼠李糖乳杆菌冻干粉贮藏12个月时,存活率仍高达94.0%。
Description
技术领域
本发明属于微生物技术领域,特别涉及一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用。
背景技术
甘油三酯(TG)是3分子长链脂肪酸和甘油形成的脂肪分子,是人体内含量最多的脂类,大部分组织均可以利用甘油三酯分解产物供给能量,同时肝脏、脂肪等组织还可以进行甘油三酯的合成,在脂肪组织中贮存,是体内能量的主要来源。
然而随着生活水平的不断提高,出现高血脂的人的比例却越来越高,某项统计数据显示,我国成年人中,出现高血脂问题的比例大约在40%左右,而且这个比例仍然在不断扩大,不断的向低龄化的趋势发展。体内甘油三酯过高会引发人体许多疾病,如高血压、动脉粥样硬化、心血管疾病等。目前防治高脂血症的主要办法有合理饮食、适量运动、适当的理疗和药物治疗,但是对于严重的高脂血症进行长期的药物治疗会出现明显的副作用,包括睡眠问题、腹泻或便秘、记忆或精神问题等。服用安全有效的具有降解甘油三酯功效的菌制剂食品或药品,可以避免或降低现有药物的副作用,但根据现有研究关于菌制剂的甘油三酯降解率普遍较低,列举如表1。
表1列举现有研究公开的菌制剂甘油三酯降解率
本发明中的鼠李糖乳杆菌具有较强的降甘油三脂功能,为高脂血症的人群治疗提供更多的选择。
发明内容
针对现有问题,本发明目的在于提供一株耐酸能力强、耐胃肠液能力强、具有降甘油三酯功能的鼠李糖乳杆菌及其应用,尤其在食品或药品组合物中的应用。
一株具有降甘油三酯功能的鼠李糖乳杆菌,所述的鼠李糖乳杆菌,所述菌株命名为鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013,该菌株已于2020年03月25日保藏在“中国微生物菌种保藏管理委员会普通微生物中心”,保藏地址为:北京市朝阳区北辰西路1号院3号,保藏号为CGMCC No.19510。
具有降甘油三酯功能的鼠李糖乳杆菌冻干粉,将上述的鼠李糖乳杆菌经过活化、扩培、发酵、冷冻干燥得到鼠李糖乳杆菌冻干粉。
上述的一株具有降甘油三酯功能的鼠李糖乳杆菌在制备治疗高血脂症食品或药品中的应用。
上述的一株具有降甘油三酯功能的鼠李糖乳杆菌制备具有降甘油三酯功能的食品或药品中的应用。
上述的应用,所述食品或药品的剂型是粉剂、片剂、丸剂、胶囊剂、颗粒剂或口服液。
上述的应用,所述的食品为菌剂或发酵食品、糖果、饮料。
一种发酵食品,是上述的一株具有降甘油三酯功能的鼠李糖乳杆菌作为发酵剂生产的食品。
一种药物制剂,包括有效剂量的上述的一株具有降甘油三酯功能的鼠李糖乳杆菌和药学上可接受的辅料。
一种菌剂,是含有上述的一株具有降甘油三酯功能的鼠李糖乳杆菌的菌剂。
本发明所述的鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013分离自顺产的健康6 月龄女婴粪便中,是一株耐消化道逆环境能力强的鼠李糖乳杆菌,具有乳杆菌的典型特征,革兰氏阳性,白色菌落,圆形凸起,表面光滑,边缘整齐,细胞呈短粗杆状,单个或成对、成链排列。其理化特征是:接触酶阴性,氧化酶阴性,上述鼠李糖乳杆菌CGMCCNo.19510 的细胞形态和理化实验结果详见表2。
表2鼠李糖乳杆菌CGMCC No.19510的细胞形态和理化实验结果
通过在美国生物工程信息中心(National Center for BiotechnologyInformation,NCBI) 查阅国际相关的基因库,将本发明的鼠李糖乳杆菌CGMCC No.19510的16S rDNA序列与 GenBank提交菌株序列相似性比较,鉴定菌株HCS01-013为鼠李糖乳杆菌(Lactobacillus rhamnosus),比较结果见表3。
表3鼠李糖乳杆菌CGMCC No.19510的16S rDNA序列与GenBank提交菌株序列相似性比较
本发明与现有技术相比,具有以下有益效果:
1、本发明鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013具有降甘油三酯功能,降解率达44.3%;
2、本发明鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013具有优秀的耐酸耐胆盐及耐胃肠液能力。当从口摄入进入人体时,能够以较高的存活率到达肠道;
3、本发明鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013分离自人源粪便中,应用时安全性高;
4、菌种纯化及发酵过程的培养基及中和剂采用的组分原料均为食品级,故菌株安全性高,可用于食品发酵或冻干菌粉等应用;
5、本发明鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013冻干菌粉稳定性高,在贮藏过程中能保持较高的存活率(冷藏贮藏12个月时存活率仍高达94.0%),以发挥其益生作用;
本发明提供鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013菌株或其培养液的组合物。
本发明提供鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013菌株或其培养液的食品组合物。
本发明提供鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013菌株或其培养液的药品组合物。
所述的食品组合物可以为保健食品组合物,不同适宜人群的食品组合物,发酵食品组合物。
所述食品组合物或药品组合物的剂型不受限制,例如,可以被制成粉剂、片剂、丸剂、胶囊剂、颗粒剂、口服液等。
附图说明
图1为邻硝基酚(ONP)物质的量的浓度标准曲线。
本发明所述的具有降甘油三酯功能的鼠李糖乳杆菌,所述的鼠李糖乳杆菌,所述菌株命名为鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013,该菌株已于2020年03月25日保藏在“中国微生物菌种保藏管理委员会普通微生物中心”,保藏号为CGMCCNo.19510。
具体实施方式
实施例1鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510菌株的筛选
1、初筛
将编号A1809样品进行梯度稀释,将稀释好的样液均匀涂布到酸化MRS改良培养基平板上,MRS培养基平板在37℃培养24~48h(平板放入自封袋中);
2、纯化
挑取具有目的菌株典型特征(观察形态、大小、色泽、及其透明度等)、菌落较大、活性较强的单菌落,于MRS改良培养基平板进行划线纯化培养,如此反复3~4次,直到划线平皿中菌落特征一致;
所述的酸化MRS改良培养基:蛋白胨10g/L,牛肉粉3g/L,酵母粉4g/L,磷酸氢二钾2g/L,柠檬酸2g/L,乙酸钠5g/L,葡萄糖20g/L,七水合硫酸镁0.58g/L,四水合硫酸锰0.25g/L,吐温-80 0.6g/L,碳酸钙10g/L,中性红0.05g(1%浓度5mL),番茄汁10mL/L (v/v),琼脂粉18g/L,调pH至5.5;115℃,30min灭菌;
实施例2鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510菌株的鉴定
将实施例1中分离纯化后的纯培养物通过划线、涂片镜检,进一步确定其为纯培养物后进行菌种鉴定,包括革兰氏染色试验,接触酶试验及16S rDNA全序列测序鉴定。最终鉴定分离得到的菌株为一株鼠李糖乳杆菌,命名为鼠李糖乳杆菌(Lactobacillusrhamnosus) HCS01-013,已于2020年03月25日保藏在“中国微生物菌种保藏管理委员会普通微生物中心”,保藏号为CGMCC No.19510。
上述鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013菌株为革兰氏阳性,白色菌落,圆形凸起,表面光滑,边缘整齐,细胞呈短粗杆状,单个或成对、成链排列。其理化特征是:接触酶阴性,氧化酶阴性,可利用D-阿拉伯糖、D-半乳糖、D-葡萄糖、D-果糖、D- 甘露糖、L-山梨醇、L-鼠李糖、甘露醇、山梨醇、α-甲基-D-葡萄糖甙、N-乙酰-葡糖胺、苦杏仁甙、熊果甙、七叶灵、水杨苷、纤维二糖、乳糖、蔗糖、海藻糖、松三糖、D-塔格糖、葡萄糖酸盐。
实施例3鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510菌株的耐消化道逆环境试验
鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013耐消化道的逆环境能力是其能够以较高存活率到达肠道并在肠道存活、定植生长及发挥功效的先决条件。
1、耐酸试验
将传代三次的菌液按照10%的接种量分别接种于空白对照培养基、pH3.0、pH2.0的基础MRS培养基中。37℃静置培养,于17h取样,用灭菌的生理盐水进行10倍系列稀释,分别取适宜稀释度的菌液1000μL进行混菌计数操作,每个稀释度2次重复,37℃静置培养 36~48h后计数。
耐酸试验数据指标:
不同pH条件的培养基测得的活菌数(用N′表示);空白对照试验测得的活菌数(用N0表示),其耐酸性活菌数对数比率计算公式如下:
受试菌株耐酸存活率(%)=lg cfu N′/lg cfu N0×100%;
表4HCS01-013耐酸试验数据表
由表4可知,HCS01-013菌株在pH 3.0的条件下经过17h后,存活率达88.8%,在pH2.0的条件下经过17h后,存活率达63.3%,表明该菌通过胃酸的抑制作用后仍可保持较高活性,从而发挥其益生作用。
2、耐胆盐试验
将传代三次的菌液按照10%的接种量分别接种于未含有牛胆盐(空白对照)、含有0.3%、0.5%、1.0%、1.5%浓度的MRS液体培养基中,37℃静置培养,于17h取样,测定活菌数。
耐胆盐试验数据指标:
测得空白对照的活菌数用N0表示,其他胆盐浓度条件下测得的活菌数用N″表示,其耐胆盐活菌数对数比率计算公式如下:
受试菌株耐胆盐试验存活率(%)=lgcfuN″/lgcfu N0×100%;
表5HCS01-013耐胆盐试验数据表
由表5可知,HCS01-013菌株耐胆盐能力较强,在1.5%的胆盐浓度条件下经过17h,存活率仍达96.1%。
3、模拟胃液试验
将传代三次的菌液震荡摇匀,取菌悬液10mL离心(5000×g,10min,5℃)获得菌泥,用PBS缓冲液冲洗3次,获得的菌泥重悬于10mL模拟胃液中,37℃条件下消化3h,分别于0h、3h取样测活菌数。
活化三代后的受试菌株在第三代培养液中的活菌数用N表示,经在模拟胃液培养基中消化3h后计数测得的活菌数用N#表示,受试菌株模拟胃液试验存活率计算公式如下:
受试菌株模拟胃液试验存活率(%)=lgcfu N#/lgcfuN×100%;
表6 HCS01-013模拟胃液试验数据表
由表6可知,HCS01-013菌株在模拟胃液中的存活能力较强,经3h处理后,存活率高达99.8%,其在胃内停留较长时间仍保持高活性。
4、模拟肠液试验
将传代三次的菌液震荡摇匀,取菌悬液10mL离心(5000×g,10min,5℃)获得菌泥,用PBS缓冲液冲洗3次,获得的菌泥重悬于10mL的人工肠液中,37℃条件下培养,于 0h、2h、4h分别取样测活菌数。
活化三代后的受试菌株在第三代培养液中的活菌数用N表示,经在模拟肠液培养液中培养2h、4h后计数测得的活菌数用N*表示,受试菌株模拟肠液试验存活率计算公式如下:
受试菌株模拟肠液试验存活率(%)=lgcfuN*/lgcfuN×100%;
表7 HCS01-013模拟肠液试验数据表
由表7可知,HCS01-013菌株在模拟肠液中的存活能力强,模拟肠液处理4h时后菌株存活率高达100%。
综上,说明该菌株具有较强的耐酸能力,且能够有效抵抗胃肠液的影响,从而能够在通过消化道后依然维持较高活性。
实施例4鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510降甘油三酯体外试验
1、试验菌株制备
(1)一级培养:将保藏于-80℃的菌株冻存管取出,经手握解冻,混匀,取1环菌液于MRS固体培养基平板划线,37℃静置培养36-48h;
(2)二级培养:挑单菌落至5mL MRS培养基中,37℃培养20h;
(3)三级培养:5mL菌液接种至100mLMRS培养基中,37℃培养17h;
(4)四级培养:将三级培养的菌液以3%接种量接种于100mL甘油三酯培养基中,37℃培养24h。同时将未接种菌液的甘油三酯培养基37℃培养24h。
MRS培养基:酵母蛋白胨10g/L,牛肉粉3g/L,酵母粉4g/L,磷酸二氢钾2g/L,柠檬酸2g/L,乙酸钠5g/L,葡萄糖20g/L,七水合硫酸镁0.58g/L,四水合硫酸锰0.25g/L,吐温- 800.6g/L,番茄汁10mL/L,琼脂20g/L,调pH至6.5;115℃,30min灭菌。
甘油三酯培养基配方的制备:将2%的聚乙烯醇水溶液与植物油按体积比3:1混合,用超声波处理(控制参数每次超声5s,间隔时间5s,共超声70次)后混合均匀制成植物油乳化液,作为甘油三酯的来源。将上述制备的植物油乳化液按5%的比例加入到MRS培养基中,调pH至6.5±0.2,115℃,30min灭菌,制成甘油三酯培养基并于4℃冰箱冷却备用。
2、单试剂法甘油三酯含量测定试验(GPO-PAP法)
将四级培养后的菌液及未接种菌液的甘油三酯培养基分别取10mL用冷冻离心机,4℃,4000r/min离心10min,取上清液,按甘油三酯试剂盒(南京建成生物试剂公司A110- 1-1)说明用96孔板将无菌蒸馏水、校准品、样本各取2.5μL分别加入空白孔、校准孔及样本孔中,每孔再加250μL工作液混匀,37℃孵育10min,每组三个平行,用酶标仪测定其 510nm处的OD值。
3试验结果计算方法
以如下计算公式计算乳酸菌的TG降解率。
总TG含量——未接种菌液的甘油三酯培养基中甘油三酯(TG)含量;
残留TG含量——接种菌液的甘油三酯培养基中甘油三酯(TG)含量。
鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 TG降解率为44.3%。
实施例5对照菌株降甘油三酯体外试验
试验选取了现有部分商品菌株进行对照,采用相同的GPO-PAP法测定甘油三酯降解率。试验结果见表8,对照菌株中甘油三酯降解率最高的为丹麦科汉森的动物双歧杆菌乳亚种BB-12菌株,其TG降解率为39.3%;其次为丹麦科汉森的植物乳杆菌vegestar 2.0,其TG降解率为35.7%。根据实施例4测定结果,鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013的TG降解率为44.3%,高于表8中的所有对照菌株。
表8对照菌株甘油三酯降解率
实施例6鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510冻干粉的制备
包括如下步骤:
1、菌种发酵
1.1)冻存菌种复苏:取存于低温冰箱内的符合要求的鼠李糖乳杆菌菌种冻存管,立即放入37℃水浴锅内进行菌种复苏,15~30s,至冻存管内液体全部融化;
待冻存菌种要求:经划线培养后平皿菌落形态均一,无杂菌;实验室300mL级别发酵菌液活菌数大于1.50×109cfu/mL,菌泥离心后收率大于1.3%,且经复核检测结果合格;
1.2)菌种活化:按照10%接种量,将复苏好的菌种直接接种至装有10ml基础培养基的 50ml三角瓶中,三角瓶密封,37℃培养箱恒温静置培养16.0±0.5小时;
1.3)菌种扩培:按照3%接种量,将菌种活化结束的菌悬液接种至装有100ml基础培养基的250ml三角瓶中,三角瓶密封,37℃培养箱恒温静置培养16.0±0.5小时;
1.4)一级发酵:按照3%接种量,将菌种扩培结束的菌悬液接种至装有140L优化培养基的200L发酵罐中,开启发酵罐搅拌桨,转速为60rpm,通气量为0,37℃恒温培养,发酵开始时,设定自动流加食品级NaOH以调控菌液pH值在5.50,同时校正电极,保证系统显示pH与实测值相差小于0.05;发酵进行7h开始,每0.5h监控菌液OD值,当培养时间≥8h,每15min监控菌液OD值;当连续两次OD值之差<0.4时,则停止发酵;
1.5)二级发酵:按照6%接种量,将一级发酵结束的菌悬液接种至装有150L优化培养基的200L发酵罐中,开启发酵罐搅拌桨,转速为60rpm,通气量为0,37℃恒温培养,在发酵开始时通过流加食品级NaOH溶液来维持恒定pH为5.50,同时校正电极,保证系统显示pH与实测值相差小于0.05;发酵进行4.5h开始,每0.5h监控菌液OD值,当培养时间≥5.5h,每15min监控菌液OD值;当OD值出现负增长,或连续两次OD值之差<0.2 时,发酵结束;
基础培养基组成及制备:葡萄糖20.0g/L、酵母蛋白胨10.0g/L、酵母浸出物5.0g/L、乙酸钠5.0g/L、L-苹果酸3.0g/L、柠檬酸2.0g/L、磷酸二氢钾2.0g/L、硫酸镁0.5g/L、硫酸锰0.01g/L、余量为纯化水;按照配方比例称量、溶解,用1mol/L食品级NaOH溶液调培养基pH值至6.80,115℃下灭菌30min;
优化培养基组成及制备:葡萄糖30.0g/L、酵母蛋白胨15.0g/L、酵母浸出物20.0g/L、乙酸钠5.0g/L、L-苹果酸5.0g/L、柠檬酸2.0g/L、磷酸二氢钾2.0g/L、氯化钙0.5g/L、吐温80 0.1g/L、硫酸镁0.06g/L、硫酸锰0.01g/L、余量为纯化水;按照配方比例称量、加热溶解,115℃下灭菌30min,用1mol/L食品级NaOH溶液调培养基pH值至6.20;
1.6)发酵液离心:二级发酵结束后,将发酵罐罐体温度调低,当罐内发酵液温度低于 20℃时准备离心,离心设备采用管式离心机,离心前对转鼓进行蒸汽灭菌30min,转速为13000rpm,结束进料后,空转5min,离心结束,收集菌泥。
注:1.1)—1.6)操作均需在10万级净化车间内进行。
2、冷冻干燥
配制6L冻干保护剂:称取海藻糖720.0g,谷氨酸钠60.0g,甘油60.0g,抗坏血酸钠6.0g,溶解于5154g纯化水中,115℃条件下灭菌30分钟,室温冷却后将制得的冻干保护剂冷藏于-4℃冰箱内备用;
2.1)冷冻干燥:收集菌泥2.4L,按照菌泥:冻干保护剂=1:2.5的体积比,添加冻干保护剂,并搅拌、混合均匀,以1.1L/盘装载量分装到冻干机托盘,然后将冻干机托盘放入冻干机内进行菌粉的冻干,冷冻干燥机温度设置见表6,真空度0~1.0Pa,持续冻干44小时;
表9冷冻干燥机温度设置表
2.2)环境温度25℃以下,湿度小于30%收集冻干粉,检测活菌数为1.02×1012cfu/mL;
2.3)按质量要求进行粉碎后包装。
注:2.1)—2.3)操作均需在10万级净化车间内进行。
实施例7鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013 CGMCC No.19510冻干粉稳定性
将鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013冻干粉置于温度为-4℃±2℃,湿度为42%±5%的冷藏环境中,密封贮藏12个月,分别于1个月、2个月、3个月、6个月、9个月、12个月取样测定活菌数,并根据公式计算存活率。
鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013冻干粉活菌数初检数据用N1表示,经冷藏环境贮藏后活菌数用N2表示,冻干粉稳定性试验存活率计算公式如下:
冻干粉稳定性试验存活率(%)=lgcfuN2/lgcfuN1×100%;
表10鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013稳定性试验结果
贮藏时间 | 活菌数(cfu/g) | 活菌对数值 | 存活率(%) |
初检数据 | 1.02×10<sup>12</sup> | 12.01 | —— |
1个月 | 5.70×10<sup>11</sup> | 11.76 | 97.9 |
2个月 | 4.35×10<sup>11</sup> | 11.64 | 96.9 |
3个月 | 3.10×10<sup>11</sup> | 11.49 | 95.7 |
6个月 | 1.77×10<sup>11</sup> | 11.25 | 93.7 |
9个月 | 1.55×10<sup>11</sup> | 11.19 | 93.2 |
12个月 | 1.95×10<sup>11</sup> | 11.29 | 94.0 |
由表10鼠李糖乳杆菌HCS01-013稳定性试验结果可知,整体趋势随着贮藏时间延长,冻干菌粉的活菌数及存活率有所下降,但贮藏12个月时,存活率仍高达94.0%,即通过此冻干工艺得到鼠李糖乳杆菌HCS01-013冻干菌粉的稳定性较强。
<110>汉臣氏(沈阳)儿童制品有限公司
<120>一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用
<160>1
<170>SIPOSequenceListing 1.0
<210>1
<211>1368
<212>DNA
<213>鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013
<400>1
CGGCTTCGGG TGTTACAAAC TCTCATGGTG TGACGGGCGG TGTGTACAAG GCCCGGGAAC 60
GTATTCACCG CGGCGTGCTG ATCCGCGATT ACTAGCGATT CCGACTTCGT GTAGGCGAGT 120
TGCAGCCTAC AGTCCGAACT GAGAATGGCT TTAAGAGATT AGCTTGACCT CGCGGTCTCG 180
CAACTCGTTG TACCATCCAT TGTAGCACGT GTGTAGCCCA GGTCATAAGG GGCATGATGA 240
TTTGACGTCA TCCCCACCTT CCTCCGGTTT GTCACCGGCA GTCTTACTAG AGTGCCCAAC 300
TAAATGCTGG CAACTAGTCA TAAGGGTTGC GCTCGTTGCG GGACTTAACC CAACATCTCA 360
CGACACGAGC TGACGACAAC CATGCACCAC CTGTCATTTT GCCCCCGAAG GGGAAACCTG 420
ATCTCTCAGG TGATCAAAAG ATGTCAAGAC CTGGTAAGGT TCTTCGCGTT GCTTCGAATT 480
AAACCACATG CTCCACCGCT TGTGCGGGCC CCCGTCAATT CCTTTGAGTT TCAACCTTGC 540
GGTCGTACTC CCCAGGCGGA ATGCTTAATG CGTTAGCTGC GGCACTGAAG GGCGGAAACC 600
CTCCAACACC TAGCATTCAT CGTTTACGGC ATGGACTACC AGGGTATCTA ATCCTGTTCG 660
CTACCCATGC TTTCGAGCCT CAGCGTCAGT TACAGACCAG ACAGCCGCCT GCGCCACTGG 720
TGTTCTTCCA TATATCTACG CATTTCACCG CTACACATGG AGTTCCACTG TCCTCTTCTG 780
CACTCAAGTT TCCCAGTTTC CGATGCACTT CCTCGGTTAA GCCGAGGGCT TTCACATCAG 840
ACTTAAAAAA CCGCCTGCGC TCGCTTTACG CCCAATAAAT CCGGATAACG CTTGCCACCT 900
ACGTATTACC GCGGCTGCTG GCACGTAGTT AGCCGTGGCT TTCTGGTTGG ATACCGTCAC 960
GCCGACAACA GTTACTCTGC CGACCATTCT TCTCCAACAA CAGAGTTTTA CGACCCGAAA 1020
GCCTTCTTCA CTCACGCGGC GTTGCTCCAT CAGACTTGCG TCCATTGTGG AAGATTCCCT 1080
ACTGCTGCCT CCCGTAGGAG TTTGGGCCGT GTTTCAGTCC CAATGTGGCC GATCAACCTC 1140
TCAGTTCGGC TACGTATCAT TGCCTTGGTG AGCCGTTACC TCACCAACTA GCTAATACGC 1200
CGCGGGTCCA TCCAAAAGCG ATAGCTTACG CCATCTTTCA GCCAAGAACC ATGCGGTTCT 1260
TGGATTTATG CGGTATTAGC ATCTGTTTCC AAATGTTATC CCCCACTTAA GGGCAGGTTA 1320
CCCACGTGTT ACTCACCCGT CCGCCACTCG TTCAAAATTA AATCAAGA 1368
Claims (9)
1.一株具有降甘油三酯功能的鼠李糖乳杆菌,其特征在于,所述的鼠李糖乳杆菌,所述菌株命名为鼠李糖乳杆菌(Lactobacillus rhamnosus)HCS01-013,该菌株已于2020年03月25日保藏在“中国微生物菌种保藏管理委员会普通微生物中心”,保藏号为CGMCCNo.19510。
2.具有降甘油三酯功能的鼠李糖乳杆菌冻干粉,其特征在于,将权利要求1所述的鼠李糖乳杆菌经过活化、扩培、发酵、冷冻干燥得到鼠李糖乳杆菌冻干粉。
3.权利要求1所述的一株具有降甘油三酯功能的鼠李糖乳杆菌在制备治疗高血脂症食品或药品中的应用。
4.权利要求1所述的一株具有降甘油三酯功能的鼠李糖乳杆菌制备具有降甘油三酯功能的食品或药品中的应用。
5.根据权利要求3或4所述的应用,其特征在于,所述食品或药品的剂型是粉剂、片剂、丸剂、胶囊剂、颗粒剂或口服液。
6.根据权利要求3或4所述的应用,其特征在于,所述的食品为菌剂或发酵食品、糖果、饮料。
7.一种发酵食品,其特征在于,是以权利要求1所述的一株具有降甘油三酯功能的鼠李糖乳杆菌作为发酵剂生产的食品。
8.一种药物制剂,其特征在于,包括有效剂量的权利要求1所述的一株具有降甘油三酯功能的鼠李糖乳杆菌和药学上可接受的辅料。
9.一种菌剂,其特征在于,是含有权利要求1所述的一株具有降甘油三酯功能的鼠李糖乳杆菌的菌剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011525162.9A CN112608865A (zh) | 2020-12-22 | 2020-12-22 | 一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011525162.9A CN112608865A (zh) | 2020-12-22 | 2020-12-22 | 一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112608865A true CN112608865A (zh) | 2021-04-06 |
Family
ID=75245145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011525162.9A Pending CN112608865A (zh) | 2020-12-22 | 2020-12-22 | 一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112608865A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114617254A (zh) * | 2022-04-11 | 2022-06-14 | 江西仁仁健康产业有限公司 | 一种具有美容养颜和润肠通便功能的葡萄籽白芷桑椹酵素 |
CN115088835A (zh) * | 2022-06-13 | 2022-09-23 | 江西仁仁健康产业有限公司 | 一种具有多功能黑枸杞酵素原液及其制备工艺 |
CN116333922A (zh) * | 2023-02-10 | 2023-06-27 | 宁波希诺亚海洋生物科技有限公司 | 一株来源于深海大鱿鱼的鼠李糖乳杆菌菌株及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109536415A (zh) * | 2018-12-26 | 2019-03-29 | 汉臣氏(沈阳)儿童制品有限公司 | 一种鼠李糖乳杆菌及其应用 |
CN111154676A (zh) * | 2020-01-11 | 2020-05-15 | 浙江工商大学 | 鼠李糖乳杆菌胞外多糖及其制备方法和所用菌 |
-
2020
- 2020-12-22 CN CN202011525162.9A patent/CN112608865A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109536415A (zh) * | 2018-12-26 | 2019-03-29 | 汉臣氏(沈阳)儿童制品有限公司 | 一种鼠李糖乳杆菌及其应用 |
CN111154676A (zh) * | 2020-01-11 | 2020-05-15 | 浙江工商大学 | 鼠李糖乳杆菌胞外多糖及其制备方法和所用菌 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114617254A (zh) * | 2022-04-11 | 2022-06-14 | 江西仁仁健康产业有限公司 | 一种具有美容养颜和润肠通便功能的葡萄籽白芷桑椹酵素 |
CN115088835A (zh) * | 2022-06-13 | 2022-09-23 | 江西仁仁健康产业有限公司 | 一种具有多功能黑枸杞酵素原液及其制备工艺 |
CN116333922A (zh) * | 2023-02-10 | 2023-06-27 | 宁波希诺亚海洋生物科技有限公司 | 一株来源于深海大鱿鱼的鼠李糖乳杆菌菌株及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110343642B (zh) | 一种发酵乳杆菌及其冻干粉的制备方法 | |
CN110272842B (zh) | 一株具有减肥降脂功能的植物乳杆菌lp104 | |
CN111996147B (zh) | 一株具有降甘油三酯功能的副干酪乳杆菌及其应用 | |
CN114990011B (zh) | 一种能够降胆固醇及抑制加德纳菌的罗伊氏乳杆菌和应用 | |
CN112608865A (zh) | 一株具有降甘油三酯功能的鼠李糖乳杆菌及其应用 | |
CN116024130B (zh) | 一株降血尿酸发酵乳杆菌a21215及其应用 | |
CN110218681B (zh) | 一株发酵乳杆菌kp101及其应用 | |
CN112813003B (zh) | 一株植物乳杆菌及其在制备缓解高血脂症引发的疾病的药物或食品中的应用 | |
CN111440750B (zh) | 一株具有缓解乳糖不耐受和降甘油三酯功能的动物双歧杆菌乳亚种及其应用 | |
CN109957530A (zh) | 一种植物乳杆菌及其应用 | |
CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
CN108004155A (zh) | 植物乳杆菌pc-26菌株及其应用 | |
CN113549567B (zh) | 一株具有促排便功能的鼠李糖乳杆菌nsl0401及其应用 | |
CN114642686B (zh) | 一种复合益生菌及其延缓衰老和抗氧化的作用 | |
CN116970512A (zh) | 一种植物乳杆菌、植物乳杆菌的培养方法及其应用 | |
CN114214230A (zh) | 一株具有共聚幽门螺杆菌能力的北酸乳杆菌及其应用 | |
CN117305189A (zh) | 一种德氏乳杆菌保加利亚亚种vb183及其培养装置和应用 | |
CN114317366B (zh) | 菌株及其应用 | |
CN113508907A (zh) | 一株耐热型发酵乳杆菌在制备促排便食品或药品中的应用 | |
CN112972505B (zh) | 一株发酵乳杆菌在制备具有降甘油三酯功能的食品或药品中的应用 | |
CN112961808A (zh) | 一种降脂减肥的乳双岐杆菌制剂及其制备方法 | |
CN116478890B (zh) | 一株调节高血糖水平的干酪乳酪杆菌及其制剂和应用 | |
CN116656526B (zh) | 一株植物乳植杆菌jf4及其在制备降血糖和降胆固醇食品药品中的应用 | |
CN116376770B (zh) | 一种鼠李糖乳酪杆菌rh0121在制备降血糖制品中的应用 | |
CN117143770B (zh) | 一株凝结魏茨曼氏菌glm336及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211101 Address after: 331200 Zhangshu North Economic and Technological Development Zone, Yichun City, Jiangxi Province Applicant after: Jiangxi Renren Health Industry Co.,Ltd. Address before: 110326 No. 35 Xingbajie, Hutai New Town, Shenyang City, Liaoning Province Applicant before: HIGH CHANGE (SHENYANG) CHILDREN'S PRODUCTS CO.,LTD. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210406 |